Aktienanalyse zu Trevi Therapeutics Inc (TRVI)TRVITrevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Trevi Therapeutics Inc is currently priced at $11.88, which is significantly below the lowest analyst price target of $23, indicating potential upside. However, the RSI is at a low 14.368, suggesting the stock is oversold and may not be a good buy at this moment. The company continues to report negative net income, with a loss of $17.8 million in Q2 2026, which poses a risk to investors. Therefore, while there is potential for recovery, the current financial performance and technical indicators suggest holding rather than buying.